

CORRESPONDENCE



Limitations of multivariate survival analysis

© The Author(s), under exclusive licence to United States & Canadian Academy of Pathology 2021

Modern Pathology (2022) 35:993; <https://doi.org/10.1038/s41379-021-00891-x>

TO THE EDITOR:

Zhu et al.¹ recently used Cox proportional hazards (CPH) analysis to evaluate the clinical significance of various clinical and pathological factors in patients with anal squamous cell carcinoma. The authors conclude that HPV status, patient age, tumor stage, and lymph node involvement by tumor, are each independently associated with the overall survival (OS) of these patients. It is likely, however, that these conclusions are inaccurate as they are derived from flawed statistical analysis.

The validity of OS analysis is inherently linked to the number of events (deaths) observed within a population rather than the overall size of the population itself. In CPH analysis, statistical validity is tied to the events per variable (EPV) ratio. This is the ratio of events (deaths) observed in a population to the number of variables analyzed. Larger EPV ratios are associated with more robust analyses, while smaller EPV ratios are increasingly susceptible to bias. To minimize the risk of introducing error in CPH analysis, it is recommended that an EPV ratio greater than 20:1 is used². Additionally, it is widely accepted that the minimum EPV ratio required to perform CPH is 10:1 and that particularly high frequencies of type-I error occur in CPH analyses with an EPV ratio of less than 5:1^{3–7}.

Zhu et al. fail to specify the number of events (deaths) observed in their cohort. Instead, they list that 74 patients were “free” of cancer and 37 patients were “not free” of cancer¹. If one assumes that the patients listed as “cancer free” were alive at their most recent follow-up, and that all of the patients listed as “not free” of cancer may have died, this leaves a maximum of 37 potential deaths (events) in the cohort. Given that the authors analyze eight variables in their CPH model (HPV status, patient age, gender, T stage, lymph node involvement, surgery, radiation, and chemotherapy), the EPV ratio could not have been greater than 4.6:1. This is markedly lower than the widely recommended EPV ratio of 20:1 and the minimum required EPV ratio of 10:1. Moreover, Zhu et al. included both continuous and categorical variables in their CPH analysis. CPH models that include both continuous and categorical variables are more likely to introduce an error than CPH models containing either continuous or categorical variables alone. As such, a minimum EPV ratio of 40:1 has been recommended for CPH models that combine both continuous and categorical variables⁶.

The EPV ratio Zhu et al. used to perform their CPH analysis falls considerably short of the thresholds required for adequate CPH analysis. It is thus likely that their CPH results, and the conclusions derived from them, are biased. The incorrect application and interpretation of statistical analysis leads to the incorrect reporting of data which may mislead the medical field^{3, 8–10}. To avoid these inaccuracies, it is imperative that researchers inform themselves of the correct applications and the limitations of the statistical tests

they use. We sincerely hope that this article brings attention to the limitations of CPH analysis and encourages researchers to respect these limitations.

Maximiliano Ramia de Cap^{1,2}✉ and Sumedh Kaul³

¹Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA. ²Harvard Medical School, Boston, MA, USA.

³Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA. ✉email: mramia@bidmc.harvard.edu

REFERENCES

- Zhu, X. et al. Molecular and immunophenotypic characterization of anal squamous cell carcinoma reveals distinct clinicopathologic groups associated with HPV and TP53 mutation status. *Mod. Pathol.* **34**, 1017–1030 (2021).
- Ogundimu, E. O., Altman, D. G. & Collins, G. S. Adequate sample size for developing prediction models is not simply related to events per variable. *J. Clin. Epidemiol.* **76**, 175–182 (2016).
- Bradburn, M. J., Clark, T. G., Love, S. B. & Altman, D. G. Survival analysis part III: multivariate data analysis—choosing a model and assessing its adequacy and fit. *Br. J. Cancer* **89**, 605–611 (2003).
- Peduzzi, P., Concato, J., Feinstein, A. R. & Holford, T. R. Importance of events per independent variable in proportional hazards regression analysis II. Accuracy and precision of regression estimates. *J. Clin. Epidemiol.* **48**, 1503–1510 (1995).
- Harrell, F. *Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis.* (Springer Science & Business Media, 2015).
- Austin, P. C., Allignol, A. & Fine, J. P. The number of primary events per variable affects estimation of the subdistribution hazard competing risks model. *J. Clin. Epidemiol.* **83**, 75–84 (2017).
- Harrell, F., Lee, K. & Mark, D. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. *Stat. Med.* **28**, 361–387 (1996).
- Ioannidis, J. P. A. Why most published research findings are false. *PLoS Med.* **2**, e124 (2005).
- Ramia de Cap, M. Multifocal papillary thyroid carcinoma. *Am. J. Clin. Pathol.* **155**, 913 (2021).
- Altman, D. G. The scandal of poor medical research. *BMJ* **308**, 283 (1994).

AUTHOR CONTRIBUTIONS

M.R. and S.K. contributed equally to this paper.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to M.R.d.C.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 14 July 2021 Revised: 20 July 2021 Accepted: 20 July 2021
Published online: 7 August 2021